Dyne Therapeutics, Inc. Interest Expense
Dyne Therapeutics, Inc. (DYN) reported Interest Expense of $2.90 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2025-11-05
- Dyne Therapeutics, Inc. interest expense for the quarter ending 2025-09-30 was $2.90M.
- Dyne Therapeutics, Inc. interest expense for the quarter ending 2025-06-30 was $94.00K.
- Dyne Therapeutics, Inc. interest expense for the quarter ending 2024-09-30 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month |
|---|---|---|---|
| 2025-09-30 | $2.90M 10-Q · filed 2025-11-05 | $3.00M derived: sum of 2 quarters · filed 2025-11-05 | $3.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $94.00K 10-Q · filed 2025-07-28 | $94.00K 10-Q · filed 2025-07-28 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |